Nucleotide sequence coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses

• US 8,709,426 B2
• Filed: 10/05/2007
• Issued: 04/29/2014
• Est. Priority Date: 02/12/1991
• Status: Expired due to Fees

• Current Assignee: Aventis Pharma SA (Sanofi )
• Original Assignee: Aventis Pharma SA (Sanofi )
• Inventors: Roman-Roman, Sergio, Ferradini, Laurent, Hercend, Thierry, Triebel, Frederic
• Primary Examiner(s): SKELDING, ZACHARY S
• Application Number:
  US11/867,862
• Publication Number:
  US 20080069770A1
• Time in Patent Office: 2,398 Days
• Field of Search: None
• US Class Current: 424/144.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 14/7051 T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 16/2809 against the T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins

Abstract

The present invention relates to new nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses.

Claims

1. An isolated antibody, or an antigen binding fragment thereof, directed against an antigenic determinant of a Vβ

peptide encoded by a nucleic acid sequence selected from the group consisting of;

nucleotides 54 to 395 of SEQ ID NO;

3,

nucleotides 18 to 329 of SEQ ID NO;

4, and

nucleotides 28 to 366 of SEQ ID NO;

5,

wherein the antibody, or antigen binding fragment thereof, specifically binds to the Vβ

peptide.

2. The antibody or an antigen binding fragment of claim 1, which is a monoclonal antibody or an antigen binding fragment thereof.

3. The antigen binding fragment of claim 2, wherein the fragment is selected from the group consisting of a Fab fragment, a Fab′

fragment, and a (Fab′

)₂ fragment.

4. A diagnostic composition comprising the monoclonal antibody of claim 2.

5. A diagnostic composition comprising the antigen binding fragment of claim 3.

6. A therapeutic composition comprising the monoclonal antibody of claim 2.

7. A therapeutic composition comprising the antigen binding fragment of claim 3.

8. The therapeutic composition of claim 6, wherein the composition further comprises a cytotoxic molecule or a radio-isotope.

9. The therapeutic composition of claim 7, wherein the composition further comprises a cytotoxic molecule or a radio-isotope.

10. A composition comprising the monoclonal antibody or antigen binding fragment of claim 2, and one or more anti-CD3 antibodies.

11. A composition comprising the antigen binding fragment of claim 3, and one or more anti-CD3 antibodies.